Eton Pharmaceuticals Financial Statements
NASDAQ: ETONHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Eton Pharmaceuticals revenue and earnings
In fiscal 2025, Eton Pharmaceuticals generated $80.0 million in revenue, up 104.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Eton Pharmaceuticals reported a net loss of $4.6 million, compared with a loss of $3.8 million a year earlier. Gross margin was 53.5% (down from 60.0%) and operating margin -1.1%.
Over the last 5 fiscal years, ETON's revenue has grown at a 359.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Eton Pharmaceuticals income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 79.95M | 39.01M | 31.64M | 21.25M | 21.83M | 39.00K | 959.00K | — |
| Revenue growth (YoY) | +104.94% | +23.29% | +48.90% | -2.66% | +55879.49% | -95.93% | — | — |
| Cost of Revenue | 37.21M | 15.60M | 10.58M | 6.93M | 2.83M | 436.00K | 453.00K | — |
| Gross Profit | 42.74M | 23.41M | 21.06M | 14.32M | 19.00M | -397.00K | 506.00K | — |
| Operating Expenses | 43.58M | 26.01M | 22.25M | 22.58M | 20.50M | 26.71M | 19.11M | 10.32M |
| Research & Development | 7.76M | 3.25M | 3.32M | 4.00M | 6.24M | 14.10M | 11.55M | 5.63M |
| Operating Income | -844.00K | -2.60M | -1.19M | -8.26M | -1.50M | -27.11M | -18.60M | -10.32M |
| Interest Expense | 4.78M | 2.00M | 1.06M | 955.00K | 1.04M | 884.00K | 98.00K | — |
| Other Income (Expense) | -3.71M | -1.21M | 503.00K | -761.00K | -1.01M | -859.00K | 281.00K | 164.00K |
| Pretax Income | -4.56M | -3.81M | -689.00K | -9.02M | -1.96M | -27.97M | -18.32M | -12.74M |
| Income Tax | 43.00K | 15.00K | 247.00K | 0 | 0 | — | — | — |
| Net Income | -4.60M | -3.82M | -936.00K | -9.02M | -1.96M | -27.97M | -18.32M | -12.74M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.17 | -0.15 | -0.04 | -0.36 | -0.08 | -1.33 | -1.03 | -5.80 |
| EPS (Diluted) | — | — | — | — | -0.08 | -1.33 | -1.03 | -5.80 |
| Shares Outstanding (Basic) | 26.91M | 25.90M | 25.65M | 25.15M | 25.21M | 21.01M | 17.76M | 6.42M |
| Shares Outstanding (Diluted) | — | — | — | — | 25.21M | 21.01M | 17.76M | 6.42M |
| EBITDA | 3.20M | -1.45M | -291.00K | -8.19M | -1.34M | -26.76M | -18.32M | -10.26M |
| Gross Margin | 53.46% | 60.01% | 66.56% | 67.38% | 87.05% | -1017.95% | 52.76% | — |
| Operating Margin | -106.00% | -6.66% | -3.77% | -38.87% | -6.85% | -69515.38% | -1939.62% | — |
| Net Margin | -5.75% | -9.80% | -2.96% | -42.45% | -8.95% | -71717.95% | -1910.32% | — |
This table shows 8 annual periods of Eton Pharmaceuticals's income statement, from FY 2025 back to FY 2018, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow ETON's reporting calendar. What is a income statement?